Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects | Zendy

Yuuichi Sakurai | Zendy; Akira Nishimura | Zendy; Gale Kennedy | Zendy; Mark G. Hibberd | Zendy; Richard O. Jenkins | Zendy; Hiroyuki Okamoto | Zendy; Tomoki Yoneyama | Zendy; Helen Jenkins | Zendy; Kiyoshi Ashida | Zendy; Shin Irie | Zendy; Jörg Täubel | Zendy

Open Access

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

Author(s) -

Yuuichi Sakurai,

Akira Nishimura,

Gale Kennedy,

Mark G. Hibberd,

Richard O. Jenkins,

Hiroyuki Okamoto,

Tomoki Yoneyama,

Helen Jenkins,

Kiyoshi Ashida,

Shin Irie,

Jörg Täubel

Publication year - 2015

Publication title -

clinical and translational gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.673

H-Index - 35

ISSN - 2155-384X

DOI - 10.1038/ctg.2015.18

Subject(s) - tolerability , pharmacokinetics , medicine , pharmacodynamics , adverse effect , pharmacology , placebo , gastroenterology , pathology , alternative medicine

Single oral doses of TAK-438 20-120 mg caused rapid, profound, and 24-h suppression of gastric acid secretion in healthy male subjects, regardless of geographical region, and TAK-438 was well tolerated at all doses studied, making it a potential alternative to proton pump inhibitors for the treatment of acid-related disorders.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research